Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon’s shareholder Thomas Wiggans filed a notice covering the proposed sale of 2,000 shares of common stock through Fidelity Brokerage Services LLC on 07/15/2026 on NASDAQ, with an indicated value of 12,630.01.
A related table ties these 2,000 common shares to a “Stock Option Exercise” from the issuer on 07/15/2026, with cash noted as consideration. Over the prior three months, Wiggans reported selling 1,000 common shares on 07/14/2026 for a value of 5,605.00.
Annexon, Inc. ownership disclosure: Redmile Group, LLC and affiliated persons report beneficial ownership stakes in the company's common stock as of July 8, 2026. Redmile Group and Jeremy C. Green each report 17,918,459 shares (representing 9.9% of the class) including warrants, and RedCo II Offshore SPV LLC reports 9,802,458 shares (representing 5.5%).
The filing states these totals include 3,369,563 shares issuable upon exercise of pre-funded warrants and cites 163,842,538 shares outstanding as of May 4, 2026 plus 15,521,422 shares issuable under the warrants for percentage calculation. The disclosure adds RedCo II Offshore SPV LLC as a reporting person after it crossed the 5% threshold.
Annexon Inc. Schedule 13G/A shows FMR LLC beneficially owns 19,518,496.35 shares of common stock, representing 11.9% of the class as of 06/30/2026. The filing lists sole dispositive power of 19,518,496.35 shares and sole voting power of 19,492,404 shares. The filing is an amendment and notes a power of attorney and an attached 13d-1(k) exhibit.
Annexon, Inc. director William D. Waddill received a grant of stock options covering 65,000 shares of common stock at an exercise price of 4.70 per share. These options vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, as long as he continues serving as a director, and expire on June 11, 2036. Following this grant, he holds 65,000 options, reflecting routine equity-based director compensation rather than an open-market trade.
Annexon, Inc. director Muneer A. Satter received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting after that date, contingent on his continued board service.
Annexon, Inc. director William A. Jones Jr. received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 11, 2036.
The underlying shares vest and become exercisable in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to his continuous service as a director until vesting.
Annexon, Inc. director Bettina M. Cockroft received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.7000 per share and expire on June 11, 2036.
According to the terms, all 65,000 underlying shares vest and become exercisable as to 100% of the total on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to her continuous service as a director until the vesting date.
Annexon, Inc. director Jung Choi received a grant of stock options covering 65,000 shares of common stock at an exercise price of $4.70 per share. These options vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to continued board service, and expire on June 11, 2036. Following this award, Choi holds stock options for 65,000 underlying shares directly.
Annexon director William H. Carson received a grant of stock options covering 65,000 shares of Annexon common stock, with an exercise price of $4.70 per share. These options were awarded as compensation rather than bought in the open market.
The options vest and become fully exercisable as to 100% of the shares on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, as long as he continues serving as a director through vesting. The options expire on June 11, 2036, and following this grant he holds derivative rights over 65,000 shares.